Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 401

1.

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS.

Thorac Cancer. 2019 Sep 11. doi: 10.1111/1759-7714.13195. [Epub ahead of print]

PMID:
31509890
2.

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.

Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, Kim KH, Kim JS, Kim TM, Kim DW, Lee JS, Heo DS.

Lung Cancer. 2019 Aug 29;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. [Epub ahead of print]

PMID:
31494530
3.

First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.

Kim R, Keam B, Hahn S, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11.

PMID:
31164319
4.

Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.

Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim JW, Lee KW, Jeon YK, Jung KC, Chung EJ, Kwon SK, Ahn SH, Sung MW, Heo DS.

Sci Rep. 2019 May 22;9(1):7680. doi: 10.1038/s41598-019-44206-2.

5.

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.

Lee Y, Kim TM, Kim DW, Kim S, Kim M, Keam B, Ku JL, Heo DS.

J Thorac Oncol. 2019 Sep;14(9):1556-1566. doi: 10.1016/j.jtho.2019.05.006. Epub 2019 May 17.

PMID:
31108249
6.

NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.

Park HR, Ahn YO, Kim TM, Kim S, Kim S, Lee YS, Kim M, Keam B, Kim DW, Heo DS.

Cytotherapy. 2019 Jun;21(6):603-611. doi: 10.1016/j.jcyt.2019.03.312. Epub 2019 Apr 20.

PMID:
31010733
7.

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Choi M, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.

PMID:
31010639
8.

A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Keam B, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS.

Oncologist. 2019 Jun;24(6):751-e231. doi: 10.1634/theoncologist.2019-0070. Epub 2019 Feb 22.

9.

Correction to: The impact of caregiver's role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver's disclosure of terminal disease status.

Yoo SH, Yun YH, Kim KN, Lee JL, Park J, Choi YS, Lim YK, Kim S, Jeong HS, Kang JH, Oh HS, Park JC, Kim SY, Song HS, Lee KS, Heo DS, Hong YS.

Qual Life Res. 2019 Jun;28(6):1693. doi: 10.1007/s11136-019-02124-w.

PMID:
30790153
10.

Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases.

Chung EJ, Jeong WJ, Jung YH, Kwon SK, Kwon TK, Ahn SH, Sung MW, Keam B, Heo DS, Kim JH, Wu HG, Lee KW, Eom KY, Rho YS.

Oral Oncol. 2019 Feb;89:84-94. doi: 10.1016/j.oraloncology.2018.12.015. Epub 2018 Dec 27.

PMID:
30732965
11.

The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.

Kim JS, Keam B, Heo DS, Han DH, Rhee CS, Kim JH, Jung KC, Wu HG.

Cancer Res Treat. 2019 Jan 29. doi: 10.4143/crt.2018.503. [Epub ahead of print]

12.

Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.

Jung M, Kim S, Lee JK, Yoon SO, Park HS, Hong SW, Park WS, Kim JE, Kim J, Keam B, Kim HJ, Kang HJ, Kim DW, Jung KC, Kim YT, Heo DS, Kim TM, Jeon YK.

Oncologist. 2019 Aug;24(8):e740-e748. doi: 10.1634/theoncologist.2018-0477. Epub 2019 Jan 29.

PMID:
30696721
13.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS.

Cancer Res Treat. 2019 Jul;51(3):1231-1240. doi: 10.4143/crt.2018.486. Epub 2018 Dec 31.

14.

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.

Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, Kim YJ, Kim TM, Jeon YK, Kim DW, Chung DH, Lee JS, Heo DS.

BMC Cancer. 2019 Jan 7;19(1):19. doi: 10.1186/s12885-018-5214-8.

15.

Factors That Influence Attitudes Toward End-of-Life Care Among Medical Students: Nationwide Survey for Fourth-Year Korean Medical Students.

Kim DY, Kim KJ, Shin SJ, Heo DS, Lee SN, Nam EM.

Am J Hosp Palliat Care. 2019 Jun;36(6):460-465. doi: 10.1177/1049909118822287. Epub 2019 Jan 6.

PMID:
30614241
16.

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.

Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, Kim DW, Heo DS.

Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.

PMID:
30546955
17.

Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?

Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, Kwon TK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2018 Nov 16. doi: 10.3904/kjim.2017.397. [Epub ahead of print]

18.

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS.

Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10.

19.

Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer.

Chun SJ, Keam B, Heo DS, Kim KH, Sung MW, Chung EJ, Kim JH, Jung KC, Kim JH, Wu HG.

Radiat Oncol J. 2018 Sep;36(3):192-199. doi: 10.3857/roj.2018.00311. Epub 2018 Sep 30.

20.

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS.

Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.

21.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

22.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2019 Sep;34(5):1116-1124. doi: 10.3904/kjim.2018.011. Epub 2018 Jun 29.

23.

High content screen for identifying small-molecule LC3B-localization modulators in a renal cancer cell line.

Kolla L, Heo DS, Rosenberg DP, Barlow SA, Maximova AA, Cassio EE, Buchser WJ.

Sci Data. 2018 Jun 26;5:180116. doi: 10.1038/sdata.2018.116.

24.

Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.

Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, Kim CW, Jeon YK.

Oncoimmunology. 2018 Mar 13;7(7):e1442164. doi: 10.1080/2162402X.2018.1442164. eCollection 2018.

25.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

26.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2019 Jan;51(1):169-177. doi: 10.4143/crt.2017.491. Epub 2018 Apr 5.

27.

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.

Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, Kim BS, Kang JH, Lee KH, Kim SW, Ryoo HM, Kim JS, Lee KH, Kwon JH, Choi JH, Shin SW, Hahn S, Heo DS.

Cancer Res Treat. 2019 Jan;51(1):119-127. doi: 10.4143/crt.2018.019. Epub 2018 Mar 12.

28.

CD21-independent Epstein-Barr virus entry into NK cells.

Lee JH, Choi J, Ahn YO, Kim TM, Heo DS.

Cell Immunol. 2018 May;327:21-25. doi: 10.1016/j.cellimm.2018.01.011. Epub 2018 Jan 17.

PMID:
29499908
29.

The impact of caregiver's role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver's disclosure of terminal disease status.

Yoo SH, Yun YH, Kim KN, Lee JL, Park J, Choi YS, Lim YK, Kim S, Jeong HS, Kang JH, Oh HS, Park JC, Kim SY, Song HS, Lee KS, Heo DS, Hong YS.

Qual Life Res. 2018 Jun;27(6):1571-1581. doi: 10.1007/s11136-018-1814-7. Epub 2018 Feb 24. Erratum in: Qual Life Res. 2019 Feb 21;:.

PMID:
29478132
30.

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.

Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, Keam B, Kim TM, Kim JS, Choi IS, Heo DS.

Korean J Intern Med. 2019 Jul;34(4):894-901. doi: 10.3904/kjim.2017.174. Epub 2018 Feb 23.

31.

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS.

Yonsei Med J. 2018 Mar;59(2):202-210. doi: 10.3349/ymj.2018.59.2.202.

32.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

33.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

34.

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.

Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4.

PMID:
29204702
35.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS.

Korean J Intern Med. 2019 Jul;34(4):885-893. doi: 10.3904/kjim.2017.036. Epub 2017 Nov 20.

36.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.

37.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

38.

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):720-728. doi: 10.4143/crt.2017.169. Epub 2017 Jul 14.

39.

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives.

Koh SJ, Kim S, Kim J, Keam B, Heo DS, Lee KH, Kim BS, Kim JH, Chang HJ, Baek SK.

Cancer Res Treat. 2018 Apr;50(2):614-623. doi: 10.4143/crt.2016.446. Epub 2017 Jul 3.

40.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.

41.

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS.

J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.

PMID:
28498782
42.

Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience.

Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, Paik JH, Lee JM, Lee HY, Lee JS, Heo DS, Lee JO.

Leuk Lymphoma. 2017 Nov;58(11):2624-2632. doi: 10.1080/10428194.2017.1312376. Epub 2017 May 9.

PMID:
28482727
43.

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.

Park S, Kim JY, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Heo DS.

Korean J Intern Med. 2017 May;32(3):514-522. doi: 10.3904/kjim.2015.299. Epub 2017 Apr 14.

44.

Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.

Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA.

Cancer Res Treat. 2017 Oct;49(4):1033-1043. doi: 10.4143/crt.2016.413. Epub 2017 Apr 7.

45.

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS.

Am J Pathol. 2017 May;187(5):980-986. doi: 10.1016/j.ajpath.2017.01.004. Epub 2017 Mar 9.

PMID:
28284718
46.

Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.

Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Kim NJ, Heo DS, Park WB, Oh MD.

Cancer. 2017 Mar 1;123(5):841-848. doi: 10.1002/cncr.30468. Epub 2016 Dec 20.

47.

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.

Shin J, Keam B, Kim M, Park YS, Kim TM, Kim DW, Kim YW, Heo DS.

J Thorac Oncol. 2017 Mar;12(3):520-528. doi: 10.1016/j.jtho.2016.11.2216. Epub 2016 Nov 17.

48.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Park S, Park S, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Kim YW, Heo DS.

Korean J Intern Med. 2016 Nov;31(6):1140-1149. Epub 2016 Mar 28.

49.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.

Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K.

Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.

PMID:
27803005
50.

Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.

Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK.

Virchows Arch. 2016 Nov;469(5):581-590. Epub 2016 Sep 5.

PMID:
27595782

Supplemental Content

Support Center